

American Urological Association

# AUA2022 Annual Meeting

May 13-16, 2022



You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

## Friday, May 13, 2022

### PD10: Bladder Cancer: Invasive II

Room 2551:10PM–1:20PM CDT

AvelumabPD10-02

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up Results From the JAVELIN Bladder 100 Trial  
Bellmunt J  
*Presentation is supported by Merck-EMD and Pfizer Alliance.*

View Presentation

## Saturday, May 14, 2022

### MP27:Prostate Cancer: Advanced (including Drug Therapy) I

Room 22210:30AM–11:45AM CDT

EnzalutamideMP27-14

Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial  
Iguchi T  
*Presentation is supported by Astellas Pharma Inc.*

View Presentation

RelugolixMP27-16

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study  
Mehlhaff B  
*Presentation is supported by Myovant.*

View Presentation

## Sunday, May 15, 2022

### PD35: Prostate Cancer: Advanced (including Drug Therapy) II

Room 2528:10AM–8:20AM CDT

RelugolixPD35-08

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Pooled Safety Analyses from Randomized Controlled Studies  
Shore N  
*Presentation is supported by Myovant.*

View Presentation

### MP48: Prostate Cancer: Advanced (including Drug Therapy) III

Room 2252:45PM–4:00PM CDT

RelugolixMP48-04

Evaluating Cardiovascular Risk in Men Starting Androgen Deprivation Therapy for Prostate Cancer  
Lowentritt B  
*Presentation is supported by Myovant.*

View Presentation